Factor Ⅺ(F Ⅺ) plays a major role in thrombus amplification and an ancillary role in hemostasis. This differential contribution is expected to provide new ideas for the prevention and treatment of thrombotic diseases by targeting F Ⅺ as a potentially safer anticoagulation strategy. Currently,an increasing number of F Ⅺ inhibitors are entering phase Ⅲ clinical trials,and although these inhibitors showed promising clinical potential,the strategies for monitoring and reversing the effects of these inhibitors remain unclear,which poses new challenges for laboratory monitoring and clinical practice. This review,based on the physiological function of F Ⅺ and F Ⅺ inhibitors under study,systematically explored the laboratory evidence of coagulation activity linked to these inhibitors,summarized potential methods of reversal in combination with the treatment protocols of inherited F Ⅺ deficiency,which provided certain references for the development of clinical treatment protocols and reversal strategies.
维普
万方数据